ASX:TLXBiotechs
How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story
Telix Pharmaceuticals recently reported that China’s NMPA accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px, while the first U.S. patient was dosed in the BiPASS Phase 3 trial assessing Illuccix and Gozellix in pre-biopsy diagnosis.
Early data showing high positive predictive value in Chinese patients and a trial aimed at reducing unnecessary biopsies highlight how Telix’s PSMA-PET portfolio could influence prostate cancer care pathways across major...